Loading...

PE anti-human CD62L Antibody

Pricing & Availability
Clone
DREG-56 (See other available formats)
Regulatory Status
RUO
Workshop
V S056
Other Names
L-selectin, LECAM-1, LAM-1, Leu-8, TQ-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
DREG-56
Human peripheral blood lymphocytes stained with DREG-56 PE
  • DREG-56
    Human peripheral blood lymphocytes stained with DREG-56 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
304805 25 tests 98 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304840 100 µg 231 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304806 100 tests 237 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L binds to carbohydrates present on certain glycoforms of CD34, glycam-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee, Cow
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Concentrated supernatant from PMA-activated human peripheral blood leukocytes
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: Western blotting2,3,9 and in vitro blocking of lymphocytes binding to high endothelial venules (HEV)2. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 304853-304858).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Kishimoto TK, et al. 1990. Proc. Natl. Acad. Sci. USA 87:2244. (WB, Block)
  3. Jutila M, et al. 2002. J. Immunol. 169:1768. (WB)
  4. Tamassia N, et al. 2008. J. Immunol. 181:6563. (FC) PubMed
  5. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Koenig JM, et al. 1996. Pediatr. Res. 39:616. (WB)
  10. Shi C, et al. 2011. J. Immunol. 187:5293. (FC) PubMed
  11. Burges M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
  12. Cash JL, et al. 2013. EMBO Rep. 14:999. (FC) PubMed
Product Citations
  1. Liu B, et al. 2015. J Virol. 89: 11834 - 11844. PubMed
  2. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  3. Li L, et al. 2022. FEBS J. 289:2877. PubMed
  4. Wohlgemuth L, et al. 2022. Cells. 11: . PubMed
  5. Guo A, et al. 2022. Nature. 607:135. PubMed
  6. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  7. Chen J, et al. 2023. Cell Res. 33:341. PubMed
  8. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  9. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  10. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  11. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  12. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  13. Jones N, et al. 2021. Nat Commun. 12:1209. PubMed
  14. Sung BY, et al. 2022. J Clin Invest. 132:. PubMed
  15. Hug S, et al. 2021. Front Immunol. 12:642867. PubMed
  16. Gatla H, et al. 2022. Front Med Technol. 4:850565. PubMed
  17. Wu D, et al. 2020. Biomark Res. 8:3. PubMed
  18. Carnevale J, et al. 2022. Nature. 609:174. PubMed
  19. Sureshchandra S, et al. 2021. iScience. 24:102690. PubMed
  20. Velázquez–Avila M, et al. 2019. Leukemia. 33:1337. PubMed
  21. Magri G et al. 2017. Immunity. 47(1):118-134 . PubMed
  22. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  23. Ye Z, et al. 2021. Nat Commun. 12:907. PubMed
  24. He Z, et al. 2016. Exp Hematol. 44:161-165. PubMed
  25. Burgess M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
  26. Uniken Venema WT, et al. 2019. Gastroenterology. 156:812. PubMed
  27. Lima J, et al. 2016. Reprod Sci. 10.1177/1933719116653680. PubMed
  28. Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed
  29. Bonte S, et al. 2021. Oncoimmunology. 10:1954800. PubMed
  30. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  31. Ye Z, et al. 2021. NPJ Aging Mech Dis. 7:4. PubMed
  32. Fan Z, et al. 2020. STAR Protoc. 1:100012. PubMed
  33. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  34. Messerer DAC, et al. 2020. Front Immunol. 11:571992. PubMed
  35. Tokatlian T, et al. 2022. J Immunother Cancer. 10:. PubMed
  36. Wu B, et al. 2022. Nat Commun. 13:2155. PubMed
  37. Groen B, et al. 2015. Sci Rep. 5: 13618. PubMed
  38. Johnson AJ, et al. 2021. Cancer Immunol Res. 9:1047. PubMed
  39. Anderson NR, et al. 2019. Cell Adh Migr. 13:163. PubMed
RRID
AB_314465 (BioLegend Cat. No. 304805)
AB_314465 (BioLegend Cat. No. 304840)
AB_314465 (BioLegend Cat. No. 304806)

Antigen Details

Structure
Selectin, single chain glycoprotein, 74-95 kD
Distribution

Majority of B cells, naïve T cells, subset of memory T and NK cells, monocytes, granulocytes, thymocytes

Function
Leukocyte homing, leukocyte tethering, rolling
Ligand/Receptor
CD34, GlyCAM, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Thymocytes, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References
  1. Kishimoto T, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
  2. Kishimoto T, et al. 1991. Blood 78:805.

 

Gene ID
6402 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD62L
Specificity Alt (DOES NOT SHOW ON TDS):
CD62L
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD62L on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD62L Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD62L DREG-56 FC
FITC anti-human CD62L DREG-56 FC
PE anti-human CD62L DREG-56 FC
PE/Cyanine5 anti-human CD62L DREG-56 FC
Purified anti-human CD62L DREG-56 FC,WB,Block
APC/Cyanine7 anti-human CD62L DREG-56 FC
Alexa Fluor® 488 anti-human CD62L DREG-56 FC
Alexa Fluor® 647 anti-human CD62L DREG-56 FC
Alexa Fluor® 700 anti-human CD62L DREG-56 FC
PE/Cyanine7 anti-human CD62L DREG-56 FC
PerCP/Cyanine5.5 anti-human CD62L DREG-56 FC
Pacific Blue™ anti-human CD62L DREG-56 FC
Brilliant Violet 421™ anti-human CD62L DREG-56 FC
Brilliant Violet 785™ anti-human CD62L DREG-56 FC
Brilliant Violet 650™ anti-human CD62L DREG-56 FC
PE/Dazzle™ 594 anti-human CD62L DREG-56 FC
Brilliant Violet 605™ anti-human CD62L DREG-56 FC
Purified anti-human CD62L (Maxpar® Ready) DREG-56 FC,CyTOF®
APC/Fire™ 750 anti-human CD62L DREG-56 FC
Brilliant Violet 510™ anti-human CD62L DREG-56 FC
TotalSeq™-A0147 anti-human CD62L DREG-56 PG
TotalSeq™-B0147 anti-human CD62L DREG-56 PG
TotalSeq™-C0147 anti-human CD62L DREG-56 PG
Ultra-LEAF™ Purified anti-human CD62L DREG-56 FC,Block,WB
Brilliant Violet 711™ anti-human CD62L DREG-56 FC
Spark NIR™ 685 anti-human CD62L DREG-56 FC
TotalSeq™-D0147 anti-human CD62L DREG-56 PG
APC/Fire™ 810 anti-human CD62L DREG-56 FC
FITC anti-human CD62L DREG-56 FC
PE/Dazzle™ 594 anti-human CD62L DREG-56 FC
PerCP/Fire™ 806 anti-human CD62L DREG-56 FC
APC anti-human CD62L DREG-56 FC
GMP FITC anti-human CD62L DREG-56 FC
Biotin anti-human CD62L DREG-56 FC
Spark Blue™ 574 anti-human CD62L (Flexi-Fluor™) DREG-56 FC
Go To Top Version: 2    Revision Date: 05.21.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account